SCHEMBL10094254

SCHEMBL10094254

CC(C)c1cccnc1Nc1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.54
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ DHODH Q02127 1/20 0.54
▸ NPC1 O15118 5/20 0.51
▸ HPGD P15428 3/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ IDH1 O75874 1/20 0.44
▸ LRRK2 Q5S007 1/20 0.43
▸ FLT1 P17948 3/20 0.43
▸ KDR P35968 3/20 0.43
▸ TNF P01375 1/20 0.43
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10094191 0.85 DHODH (0.51) RAB9ASMN1; SMN2MEN1KMT2ADHODH
SCHEMBL10094192 0.84 DHODH (0.54) RAB9ASMN1; SMN2MEN1KMT2ADHODH
SCHEMBL10094180 0.83 NPC1 (0.47) RAB9ASMN1; SMN2MEN1KMT2ADHODH
SCHEMBL9839208 0.81 RAB9A (0.54) RAB9ASMN1; SMN2MEN1KMT2ADHODH
SCHEMBL10094204 0.80 HPGD (0.58) RAB9ASMN1; SMN2MEN1KMT2ADHODH
SCHEMBL10094260 0.78 ADRA2A (0.45) RAB9ASMN1; SMN2MEN1KMT2ANPC1
SCHEMBL10094166 0.77 CCNA2 (0.48) RAB9ASMN1; SMN2MEN1KMT2ANPC1
SCHEMBL10094258 0.77 GRM4 (0.54) RAB9ASMN1; SMN2MEN1KMT2ANPC1
SCHEMBL10094188 0.77 PIK3CA (0.53) RAB9ASMN1; SMN2MEN1KMT2ADHODH
SCHEMBL10094278 0.77 DHODH (0.60) RAB9ASMN1; SMN2MEN1KMT2ADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 — — US disclosed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 — — US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 — — US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 RAB9A 2246/4885SMN1; SMN2 4477/4885MEN1 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback